SS Innovations International Inc. (NASDAQ: SSII) has reported record second-quarter revenue of $13.9 million, a 39.4% increase year over year, underscoring the rising demand for its SSi Mantra surgical robotic platform. The company's first-half revenue reached $25.0 million, up 65.6% from the same period in 2025, reflecting robust commercial momentum as installations of the SSi Mantra system continue to climb.
During the quarter, SS Innovations installed 30 SSi Mantra systems, a 30.4% increase year over year, bringing the total installed base to 224 systems across 12 countries. Cumulative surgeries performed on the platform reached 12,272, demonstrating growing clinical utilization. The company's gross profit for the quarter increased 20.0% to $7.1 million, though gross margin dipped to 50.9% from 59.1% in the prior-year period, likely due to product mix and investments in scaling operations.
The strong financial performance is not just a reflection of current success but also a signal of future potential. SS Innovations is targeting FDA clearance for the SSi Mantra by the first quarter of 2027 and EU CE marking by the end of 2026. These regulatory milestones are expected to unlock significant market opportunities, particularly in the United States and Europe, where the adoption of surgical robotics is more established. The company's recent telesurgery achievements are also expanding the clinical profile of the SSi Mantra, showcasing its capabilities beyond traditional on-site procedures.
While system installations remain the primary commercial growth driver, the company's advances in telesurgery could differentiate it from competitors and open new revenue streams. The ability to perform remote surgeries has profound implications for healthcare access, especially in underserved regions. As SS Innovations continues to build its installed base and accumulate clinical data, its value proposition to hospitals and surgical centers strengthens.
The record revenue and strategic progress have not gone unnoticed by investors. The company's performance suggests that its business model is gaining traction, and with a clear roadmap for regulatory approvals, the future looks promising. However, the decline in gross margin warrants monitoring, as it could impact profitability as the company scales. Nonetheless, the strong top-line growth and expanding global footprint position SS Innovations as a key player in the surgical robotics market.
For more information on SS Innovations and its latest developments, investors can visit the company's newsroom at https://nnw.fm/SSII.
